+ Watch NVGN
on My Watchlist
The Company is a pharmaceutical company involved in the discovery, development, manufacture and marketing of products based on the emerging field of phenolic technology.
Phenoxodiol for recurrent ovarian cancer is in a phase III clinical trial (OVATURE) through the majority-owned Marshall Edwards subsidiary, and interim data from the trial is predicted to be released in mid-2008. The stock suffered during the recent biotech sector swoon but in the last month has doubled, with a 30% gain today on no news. My best guess is that the rise is based on rumors of a buyout by Novartis. The company has been de-emphasizing phenoxodiol in its press releases and hyping early clinical and preclinical compounds, which is a pattern I have seen many times to cushion the blow when a phase III trial is headed for failure. This is a very high-risk underperform based on the premise that OVATURE will be a failure and that no buyout will occur. Definitely a CAPS only play, especially since I missed the top of 10 earlier today.
Well, what was that all about? That steep climb, a choppy plateau, and now a dizzying descent? Us lowly retail investors will likely never know. But it does illustrate the advantages of keeping a close eye on the market to pick up some low-hanging fruit. I may be exiting the red thumb party early, but I'll remember these guys and jump in on the next irrational upswing.
Pardon me, I need some help.I'm new to the Motley Fool, but not to the market. Do you by chance know why it is that some stocks are listed as "not currently ratable?"
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ratings and Key Statistics provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions